This week, the ratings of seven Biotechnology stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Genomic Health, Inc.’s (NASDAQ:GHDX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. For Portfolio Grader’s specific subcategory of Earnings Revisions, GHDX also gets an F. The stock price has dropped 11.1% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.
This is a rough week for Acorda Therapeutics, Inc. (NASDAQ:ACOR). The company’s rating falls to D from the previous week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For a full analysis of ACOR stock, visit Portfolio Grader.
Amarin Corporation Plc Sponsored ADR (NASDAQ:AMRN) earns a D this week, falling from last week’s grade of C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of Oct. 8, 2013, 14.5% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. Shares of the stock have been trading at an exceptionally rapid pace, up threefold from the week prior. To get an in-depth look at AMRN, get Portfolio Grader’s complete analysis of AMRN stock.
Exelixis, Inc. (NASDAQ:EXEL) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Oct. 8, 2013, 22.6% of outstanding Exelixis, Inc. shares were held short. For a full analysis of EXEL stock, visit Portfolio Grader.
Trius Therapeutics, Inc. (NASDAQ:TSRX) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.
Discovery Laboratories, Inc. (NASDAQ:DSCO) earns a D this week, moving down from last week’s grade of C. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. To get an in-depth look at DSCO, get Portfolio Grader’s complete analysis of DSCO stock.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is having a tough week. The company’s rating falls from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also gets an F in Equity. Investors seem to agree with the downgrade and have pushed down the share price 63.7% over the past month. As of Oct. 8, 2013, 15.7% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. For a full analysis of ACHN stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.